FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133448246> ?p ?o ?g. }

• W3133448246 abstract "The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous biosafety level 3 (BSL3) conditions, which limits high-throughput screening of patient and vaccine sera. Myriad BSL2-compatible surrogate virus neutralization assays (VNAs) have been developed to overcome this barrier. Yet, there is marked variability between VNAs and how their results are presented, making intergroup comparisons difficult. To address these limitations, we developed a standardized VNA using CoV2-S pseudotyped particles (CoV2pp) based on vesicular stomatitis virus bearing the Renilla luciferase gene in place of its G glycoprotein (VSVΔG); this assay can be robustly produced at scale and generate accurate neutralizing titers within 18 h postinfection. Our standardized CoV2pp VNA showed a strong positive correlation with CoV2-S enzyme-linked immunosorbent assay (ELISA) results and live-virus neutralizations in confirmed convalescent-patient sera. Three independent groups subsequently validated our standardized CoV2pp VNA (n > 120). Our data (i) show that absolute 50% inhibitory concentration (absIC50), absIC80, and absIC90 values can be legitimately compared across diverse cohorts, (ii) highlight the substantial but consistent variability in neutralization potency across these cohorts, and (iii) support the use of the absIC80 as a more meaningful metric for assessing the neutralization potency of a vaccine or convalescent-phase sera. Lastly, we used our CoV2pp in a screen to identify ultrapermissive 293T clones that stably express ACE2 or ACE2 plus TMPRSS2. When these are used in combination with our CoV2pp, we can produce CoV2pp sufficient for 150,000 standardized VNAs/week.IMPORTANCE Vaccines and antibody-based therapeutics like convalescent-phase plasma therapy are premised upon inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) are an essential part of determining vaccine or therapeutic efficacy. However, such efficacy testing is limited by the inherent dangers of working with the live virus, which requires specialized high-level biocontainment facilities. We therefore developed a standardized replication-defective pseudotyped particle system that mimics the entry of live SARS-CoV-2. This tool allows for the safe and efficient measurement of NATs, determination of other forms of entry inhibition, and thorough investigation of virus entry mechanisms. Four independent labs across the globe validated our standardized VNA using diverse cohorts. We argue that a standardized and scalable assay is necessary for meaningful comparisons of the myriad of vaccines and antibody-based therapeutics becoming available. Our data provide generalizable metrics for assessing their efficacy." @default.
• W3133448246 created "2021-03-01" @default.
• W3133448246 creator A5000500792 @default.
• W3133448246 creator A5003224926 @default.
• W3133448246 creator A5003745569 @default.
• W3133448246 creator A5012554174 @default.
• W3133448246 creator A5021387107 @default.
• W3133448246 creator A5024835198 @default.
• W3133448246 creator A5030735456 @default.
• W3133448246 creator A5033595795 @default.
• W3133448246 creator A5035136737 @default.
• W3133448246 creator A5035258640 @default.
• W3133448246 creator A5035822052 @default.
• W3133448246 creator A5036568474 @default.
• W3133448246 creator A5038614518 @default.
• W3133448246 creator A5041332295 @default.
• W3133448246 creator A5044800751 @default.
• W3133448246 creator A5056122468 @default.
• W3133448246 creator A5057879870 @default.
• W3133448246 creator A5058015853 @default.
• W3133448246 creator A5058183468 @default.
• W3133448246 creator A5061603185 @default.
• W3133448246 creator A5062275593 @default.
• W3133448246 creator A5065664923 @default.
• W3133448246 creator A5070606892 @default.
• W3133448246 creator A5071125492 @default.
• W3133448246 creator A5077956716 @default.
• W3133448246 creator A5079676236 @default.
• W3133448246 creator A5080281376 @default.
• W3133448246 creator A5080940457 @default.
• W3133448246 creator A5083185087 @default.
• W3133448246 creator A5090567275 @default.
• W3133448246 creator A5091149619 @default.
• W3133448246 date "2021-02-23" @default.
• W3133448246 modified "2023-10-15" @default.
• W3133448246 title "Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera" @default.
• W3133448246 cites W1547753877 @default.
• W3133448246 cites W1585640238 @default.
• W3133448246 cites W1971395496 @default.
• W3133448246 cites W1971894038 @default.
• W3133448246 cites W1978118805 @default.
• W3133448246 cites W1998964868 @default.
• W3133448246 cites W2005979522 @default.
• W3133448246 cites W2006785079 @default.
• W3133448246 cites W2021540849 @default.
• W3133448246 cites W2022948223 @default.
• W3133448246 cites W2028504310 @default.
• W3133448246 cites W2033652378 @default.
• W3133448246 cites W2044139515 @default.
• W3133448246 cites W2054399251 @default.
• W3133448246 cites W2058780476 @default.
• W3133448246 cites W2064076043 @default.
• W3133448246 cites W2080374377 @default.
• W3133448246 cites W2087420232 @default.
• W3133448246 cites W2096966517 @default.
• W3133448246 cites W2097188280 @default.
• W3133448246 cites W2101506295 @default.
• W3133448246 cites W2125753032 @default.
• W3133448246 cites W2126241449 @default.
• W3133448246 cites W2126707939 @default.
• W3133448246 cites W2131643524 @default.
• W3133448246 cites W2140674451 @default.
• W3133448246 cites W2140734584 @default.
• W3133448246 cites W2151461700 @default.
• W3133448246 cites W2167384912 @default.
• W3133448246 cites W2171542740 @default.
• W3133448246 cites W2212640525 @default.
• W3133448246 cites W2264748401 @default.
• W3133448246 cites W2324835369 @default.
• W3133448246 cites W2513547424 @default.
• W3133448246 cites W2775762540 @default.
• W3133448246 cites W2990311780 @default.
• W3133448246 cites W2994156659 @default.
• W3133448246 cites W3007643904 @default.
• W3133448246 cites W3008222332 @default.
• W3133448246 cites W3008394341 @default.
• W3133448246 cites W3009912996 @default.
• W3133448246 cites W3010238729 @default.
• W3133448246 cites W3010783509 @default.
• W3133448246 cites W3010955108 @default.
• W3133448246 cites W3012650581 @default.
• W3133448246 cites W3012756997 @default.
• W3133448246 cites W3012944241 @default.
• W3133448246 cites W3013213522 @default.
• W3133448246 cites W3013742505 @default.
• W3133448246 cites W3013893137 @default.
• W3133448246 cites W3013985547 @default.
• W3133448246 cites W3014168462 @default.
• W3133448246 cites W3014185271 @default.
• W3133448246 cites W3014518605 @default.
• W3133448246 cites W3014721277 @default.
• W3133448246 cites W3014735311 @default.
• W3133448246 cites W3014912119 @default.
• W3133448246 cites W3014941429 @default.
• W3133448246 cites W3015662129 @default.
• W3133448246 cites W3015769096 @default.
• W3133448246 cites W3016266726 @default.
• W3133448246 cites W3016269138 @default.
• W3133448246 cites W3017017672 @default.
• W3133448246 cites W3017962953 @default.

• next